Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Toomey

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Thrombosis and Haemostasis : JTH|October 1, 2004
Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activationA Zivelin, T Ogawa, S Bulvik, et al.
Thrombosis Research|October 29, 2000
Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosisJ R Toomey, M N Blackburn, B L Storer, et al.
Biochemical Society Transactions|May 22, 2007
The quest for Factor VIIa exosite inhibitorsA Amour, J Hutchinson, A M Ruiz Avendaño, et al.
Journal of Thrombosis and Haemostasis : JTH|September 12, 2006
A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosisJ R Toomey, M A Abboud, R E Valocik, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 1999
Antithrombotic efficacy of a novel murine antihuman factor IX antibody in ratsG Z Feuerstein, A Patel, J R Toomey, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Thrombosis and Haemostasis : JTH|October 1, 2004
Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activationA Zivelin, T Ogawa, S Bulvik, et al.
Thrombosis Research|October 29, 2000
Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosisJ R Toomey, M N Blackburn, B L Storer, et al.
Biochemical Society Transactions|May 22, 2007
The quest for Factor VIIa exosite inhibitorsA Amour, J Hutchinson, A M Ruiz Avendaño, et al.
Journal of Thrombosis and Haemostasis : JTH|September 12, 2006
A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosisJ R Toomey, M A Abboud, R E Valocik, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 1999
Antithrombotic efficacy of a novel murine antihuman factor IX antibody in ratsG Z Feuerstein, A Patel, J R Toomey, et al.
Pageof 2